Patents Assigned to Pfizer
  • Enhanced Stability of Novel Liquid Compositions
    Publication number: 20160151280
    Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
    Type: Application
    Filed: February 4, 2016
    Publication date: June 2, 2016
    Applicant: Pfizer Inc.
    Inventors: Gary Robert Agisim, Robert Alan Friedline, Shivangi Akash Patel, Cesar Ivan Sertzen, Vanessa Rose Shepperson
  • 2-Amino-6-Methyl-4,4a,5,6-Tetrahydropyrano[3,4-d][1,3]Thiazin-8a(8H)-yl-1,3-Thiazol-4-yl Amides
    Publication number: 20160152637
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Application
    Filed: February 9, 2016
    Publication date: June 2, 2016
    Applicant: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • Processes for preparing peptide conjugates and linkers
    Patent number: 9352050
    Abstract: The present invention provides a process for preparing a compound of Formula 5b, as well as intermediates thereof, and novel classes of compounds useful in process for preparing these and similar compounds.
    Type: Grant
    Filed: December 10, 2012
    Date of Patent: May 31, 2016
    Assignee: PFIZER INC.
    Inventors: Javier Magano, Mark Thomas Maloney, Olivier J. Marcq, Durgesh Vasant Nadkarni, Mark John Pozzo, John Joseph Teixeira, Jr.
  • USE OF A TETRASUBSTITUTED PYRAZOLO[4, 3-D]PYRIMIDINE COMPOUND FOR TREATING DIABETIC NEPHROPATHY
    Publication number: 20160136170
    Abstract: The present invention relates to methods of delaying progression to end stage renal disease (ESRD) in patients comprising administration of 1-(2-ethoxyethyl)-5-(ethyl(methyl)amino)-7-((4-methylpyridin-2-yl)amino)-N-(methylsulfonyl)-1H-pyrazolo[4,3-d]pyrimidine-3-carboxamide. The present invention also includes administration of pharmaceutical compositions for delaying progression to ESRD.
    Type: Application
    Filed: January 21, 2016
    Publication date: May 19, 2016
    Applicant: Pfizer Inc.
    Inventors: Valerie Clerin, Jeremy Gale, Nihad Tamimi
  • Hydroxamic acid derivatives useful as antibacterial agents
    Patent number: 9340493
    Abstract: The invention relates to a compound of formula (I): or a pharmaceutically acceptable salt thereof, thereof, wherein: G is a group of formula (II): and pharmaceutically acceptable salts, prodrugs, hydrates, or solvates, thereof, wherein A, B, L1-L4, A, B, R1-R4, and m are as defined herein. The invention also relates to pharmaceutical compositions comprising the compounds of formula (I) and their use in treating a bacterial infection.
    Type: Grant
    Filed: March 24, 2014
    Date of Patent: May 17, 2016
    Assignee: Pfizer Inc.
    Inventors: Matthew Frank Brown, Charles Francis Donovan, Edmund Lee Ellsworth, Denton Wade Hoyer, Timothy Allan Johnson, Manjinder Singh Lall, Chris Limberakis, Sean Timothy Murphy, Debra Ann Sherry, Clarke Bentley Taylor, Joseph Scott Warmus
  • Substituted-6,8-dioxabicyclo[3.2.1]octane-2,3-diol compounds as targeting agents of ASGPR
    Patent number: 9340553
    Abstract: Compounds of Formula (A) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by pharmaceutical compositions and the uses thereof as asialoglycoprotein receptor (ASGPR) targeting agents.
    Type: Grant
    Filed: May 18, 2015
    Date of Patent: May 17, 2016
    Assignee: Pfizer Inc.
    Inventors: Spiros Liras, Vincent Mascitti, Benjamin Thuma
  • Fecal Recovery Assay
    Publication number: 20160122799
    Abstract: The fecal recovery assay of this invention accurately quantifies the number of viable BB12 colonies in the gastrointestinal tract of humans and animals. This BB12 culture method is highly selective for isolating BB12 colonies from human stool. Furthermore, this method has the utility of assessing the survivability of BB12 delivered by food products and supplements through the GI tract, and thus providing potential information on the human health effects of viable BB12.
    Type: Application
    Filed: October 2, 2015
    Publication date: May 5, 2016
    Applicant: Pfizer Inc.
    Inventors: Julie McKinney, Lori Lathrop Stern
  • Human antibodies that bind human MAdCAM
    Patent number: 9328169
    Abstract: The present invention relates to antibodies, including human antibodies, and antigen-binding portions thereof that specifically bind to MAdCAM, preferably human MAdCAM, and inhibit MAdCAM. The antibodies comprise the CDRs or variable domains derived from an antibody produced by the hybridoma cell line 7.16.6 (ECACC Accession No. 03090909) or from an antibody comprising the amino acid sequences of SEQ ID NOs.: 34 and 36. The invention also relates to nucleic acid molecules encoding such antibodies and antigen-binding portions thereof, methods of making and using the antibodies and portions, and compositions comprising these antibodies and portions.
    Type: Grant
    Filed: January 7, 2005
    Date of Patent: May 3, 2016
    Assignees: Pfizer Inc., Amgen Fremont Inc.
    Inventors: Nicholas Pullen, Elizabeth Molloy, Sirid-Aimée Kellermann, Larry L. Green, Mary Haak-Frendscho
  • Apixaban formulations
    Patent number: 9326945
    Abstract: Compositions comprising crystalline apixaban particles having a D90 equal to or less than 89 ?m, and a pharmaceutically acceptable carrier, are substantially bioequivalent and can be used to for the treatment and/or prophylaxis of thromboembolic disorders.
    Type: Grant
    Filed: February 24, 2011
    Date of Patent: May 3, 2016
    Assignees: Bristol-Myers Squibb Company, Pfizer Inc.
    Inventors: Jatin Patel, Charles Frost, Jingpin Jia, Chandra Vemavarapu
  • Selective androgen receptor modulators
    Patent number: 9328104
    Abstract: The present invention relates to a compound of Formula 1, 2 or 3: wherein A is N or —CR0—, where R0 is hydrogen, C1-C6 linear or branched chain alkyl, etc., Z is —CRe—, or, —N—, where Re is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R1 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R2 are independently hydrogen or C1-C6 linear or branched chain alkyl; R3 and R4 are independently hydrogen, C1-C6 linear or branched chain alkyl, etc.; R5 and R6 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.; R8 is hydrogen, C1-C6 linear or branched chain alkyl, etc.; R9 and R10 are independently hydrogen or C1-C6 linear or branched chain alkyl, etc.
    Type: Grant
    Filed: December 2, 2013
    Date of Patent: May 3, 2016
    Assignee: Pfizer Inc.
    Inventors: James Thomas Anderson, Eugene Lvovich Piatnitski Chekler, Edmund L. Ellsworth, Bruce Kipp Erickson, Adam Matthew Gilbert, Anthony P. Ricketts, David P. Thompson, Rayomand Jal Unwalla, Patrick Robert Verhoest
  • Tropomyosin-related kinase inhibitors
    Patent number: 9328096
    Abstract: The present invention relates to compounds of Formula I and their pharmaceutically acceptable salts, wherein the substituents are as described herein, and their use in medicine, in particular as TrkA antagonists.
    Type: Grant
    Filed: May 6, 2015
    Date of Patent: May 3, 2016
    Assignee: Pfizer Inc.
    Inventors: Sharanjeet Kaur Bagal, Jingrong Jean Cui, Samantha Elizabeth Greasley, Elizabeth Ann Lunney, Indrawan James McAlpine, Asako Nagata, Sacha Ninkovic, Kiyoyuki Omoto, Sarah Elizabeth Skerratt, Robert Ian Storer, Joseph Scott Warmus
  • SOLID FORMS OF A MACROCYCLIC KINASE INHIBITOR
    Publication number: 20160115178
    Abstract: This invention relates to crystalline solvates of (10R)-7-amino-12-fluoro-2,10,16-trimethyl-15-oxo-10,15,16,17-tetrahydro-2H-8,4-(metheno)pyrazolo[4,3-h][2,5,11]benzoxadiazacyclotetradecine-3-carbonitrile, useful in the treatment of abnormal cell growth, such as cancer, in mammals. This invention also relates to pharmaceutical compositions comprising such crystalline solvates, and to methods of using such solvates and compositions in the treatment of abnormal cell growth in mammals, especially humans.
    Type: Application
    Filed: June 17, 2014
    Publication date: April 28, 2016
    Applicant: Pfizer Inc.
    Inventors: Andrew James JENSEN, Suman LUTHRA, Paul Francis RICHARDSON
  • Device for dispensing a plurality of unitary doses of dry powder, and inhaler comprising such device
    Patent number: 9314578
    Abstract: Various embodiments relate to a device for dispensing a plurality of unitary doses of dry powder. The device includes: a casing; first and second supports respectively for two carriers each having a plurality of housings for respective unitary doses adapted to be connected to the mouthpiece for inhalation of the dose, the first and second supports being moveably mounted within the casing for sequentially connecting the housings to the mouthpiece; an indexing mechanism adapted to engage and move the first and second supports; and a changeover mechanism adapted to cause the device to pass from a first dispensing state to a second dispensing state and lock the second support in its stationary position while the device is in the first dispensing state, and to lock the first support in its stationary position while the device is in the second dispensing state.
    Type: Grant
    Filed: July 26, 2013
    Date of Patent: April 19, 2016
    Assignee: PFIZER LTD.
    Inventors: Louise Annabel Bunch, Paul George Harris
  • 2-amino-6-methyl-4,4a,5,6-tetrahydropyrano[3,4-d][1,3]thiazin-8a(8H)-yl-1,3-thiazol-4-yl amides
    Patent number: 9315520
    Abstract: The present invention is directed to compounds, tautomers and pharmaceutically acceptable salts of the compounds which are disclosed, wherein the compounds have the structure of Formula I, and the variable R1 is as defined in the specification. Corresponding pharmaceutical compositions, methods of treatment, methods of synthesis, and intermediates are also disclosed.
    Type: Grant
    Filed: April 9, 2015
    Date of Patent: April 19, 2016
    Assignee: Pfizer Inc.
    Inventors: Michael Aaron Brodney, Elizabeth Mary Beck, Christopher Ryan Butler, Lei Zhang, Brian Thomas O'Neill, Gabriela Barreiro, Erik Alphie LaChapelle, Bruce Nelsen Rogers
  • SUBSTITUTED AMIDE COMPOUNDS
    Publication number: 20160102074
    Abstract: The present invention is directed at substituted amide compounds, pharmaceutical compositions containing such compounds and the use of such compounds to reduce plasma lipid levels, such as LDL-cholesterol and triglycerides and accordingly to treat diseases which are exacerbated by high levels of LDL-cholesterol and triglycerides, such as atherosclerosis and cardiovascular diseases, in mammals, including humans.
    Type: Application
    Filed: September 29, 2015
    Publication date: April 14, 2016
    Applicant: PFIZER INC.
    Inventors: Etzer Darout, Kim F. McClure, David Piotrowski, Brian Raymer
  • Recombinant virus-like particles encoded by multi-gene vector
    Patent number: 9309536
    Abstract: The invention describes novel virus-like particles for use as vaccines, diagnostic tools and R&D tools based on recombinant DNA and cell cultivation techniques for production. The recombinant virus-like particles of the invention are assembled by polypeptide chains that incorporate several, in particular two or more, different epitopes which are selected either (a) from different viral strains of the same virus and/or (b) from different serotypes of the same virus and/or (c) from different viral strains specific for different hosts. These epitopes are then displayed on the particle surface.
    Type: Grant
    Filed: August 29, 2014
    Date of Patent: April 12, 2016
    Assignee: PFIZER INC.
    Inventors: Corinne John, Christian Schaub, Sabine Wellnitz
  • Salt forms of [R-(R*,R*)]-2-(4-fluorophenyl)-?, ?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-hepatanoic acid
    Patent number: 9309195
    Abstract: Novel salt forms of [R—(R*,R*)]-2-(4-fluorophenyl)-?,?-dihydroxy-5-(1-methylethyl)-3-phenyl-4-[(phenylamino)carbonyl]-1H-pyrrole-1-heptanoic acid characterized by their X-ray powder diffraction pattern and solid-state NMR spectra are described, as well as methods for the preparation and pharmaceutical composition of the same, which are useful as agents for treating hyperlipidemia, hypercholesterolemia, osteoporosis, benign prostatic hyperplasia, and Alzheimer's Disease.
    Type: Grant
    Filed: May 19, 2015
    Date of Patent: April 12, 2016
    Assignee: Pfizer Inc.
    Inventors: Joseph Francis Krzyzaniak, Jason Albert Leonard
  • Enhanced stability of novel liquid compositions
    Patent number: 9308166
    Abstract: The present invention relates to compositions of pharmaceutical agents in combination with additional pharmaceutical agents in a mixture of polyethylene glycol, polyvinylpyrrolidone, and propylene glycol and a process of making the compositions.
    Type: Grant
    Filed: February 27, 2014
    Date of Patent: April 12, 2016
    Assignee: Pfizer Inc.
    Inventors: Gary Robert Agisim, Robert Alan Friedline, Shivangi Akash Patel, César Iván Sertzen, Vanessa Rose Shepperson
  • Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
    Patent number: 9308204
    Abstract: Compounds of Formula (A) and (B) are described herein and the uses thereof for the treatment of diseases, conditions and/or disorders mediated by sodium-glucose transporter inhibitors (in particular, SGLT2 inhibitors).
    Type: Grant
    Filed: November 7, 2014
    Date of Patent: April 12, 2016
    Assignee: Pfizer Inc.
    Inventor: Vincent Mascitti
  • PC33718E
    Publication number: 20160096898
    Abstract: The present invention provides antagonizing antibodies, antigen-binding portions thereof, and aptamers that bind to proprotein convertase subtilisin kexin type 9 (PCSK9). Also provided are antibodies directed to peptides, in which the antibodies bind to PCSK9. The invention further provides a method of obtaining such antibodies and antibody-encoding nucleic acid. The invention further relates to therapeutic methods for use of these antibodies and antigen-binding portions thereof to reduce LDL-cholesterol levels and/or for the treatment and/or prevention of cardiovascular disease, including treatment of hypercholesterolemia.
    Type: Application
    Filed: September 24, 2015
    Publication date: April 7, 2016
    Applicants: PFIZER INC., RINAT NEUROSCIENCE CORP.
    Inventors: Hong LIANG, Yasmina Noubia ABDICHE, Javier Fernando CHAPARRO RIGGERS, Bruce Charles GOMES, Julie Jia Li HAWKINS, Jaume PONS, Xiayang QIU, Pavel STROP, Yuli WANG